Patents Assigned to AKRIBES BIOMEDICAL GMBH
  • Rucaparib, Talazoparib, Veliparib, Olaparib and AZD 2461 for treating impaired skin wound healing
    Patent number: 11638709
    Abstract: The present invention relates to Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib, and/or AZD 2461, or a pharmaceutically acceptable salt thereof, for use in the treatment of impaired skin wound healing in a subject, an in vitro method for identifying a subject suffering from impaired skin wound healing to be responsive to the treatment with Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib and/or AZD 2461, and kits and kits-of-part related thereto.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: May 2, 2023
    Assignee: AKRIBES BIOMEDICAL GMBH
    Inventors: Barbara Wolff-Winiski, Anton Stütz, Petra Dörfler
  • Methods for identifying a non-healing skin wound and for monitoring the healing of a skin wound
    Patent number: 11579141
    Abstract: The present invention relates to an in vitro method for identifying a skin wound in an individual as being a non-healing skin wound or healing skin wound, in vitro methods for monitoring the healing of a skin wound in an individual, methods for screening for compounds suitable for modulating skin wound healing, as well as kits related thereto.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: February 14, 2023
    Assignee: AKRIBES BIOMEDICAL GMBH
    Inventors: Barbara Wolff-Winiski, Anton Stütz, Petra Dörfler
  • SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING
    Publication number: 20220047602
    Abstract: The present invention relates to a Selective Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof, for use in the treatment of impaired skin wound healing in a subject, an in vitro method for identifying a subject suffering from impaired skin wound healing to be responsive to the treatment with a Selective Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof, and kits and kits-of-part related thereto.
    Type: Application
    Filed: July 20, 2021
    Publication date: February 17, 2022
    Applicant: AKRIBES BIOMEDICAL GMBH
    Inventors: Barbara WOLFF-WINISKI, Anton STÜTZ, Nicole SCHÖFMANN, Petra DÖRFLER
  • PARP Inhibitor in Combination with a Glucocorticoid and/or Ascorbic Acid and/or a Protein Growth Factor for the Treatment of Impaired Wound Healing
    Publication number: 20200129476
    Abstract: The present invention relates to a PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing.
    Type: Application
    Filed: April 24, 2018
    Publication date: April 30, 2020
    Applicant: AKRIBES BIOMEDICAL GMBH
    Inventors: BARBARA WOLFF-WINISKI, ANTON STÜTZ, PETRA DÖRFLER
  • Rucaparib, Talazoparib, Veliparib, Olaparib and AZD 2461 for Treating Impaired Skin Wound Healing
    Publication number: 20200078369
    Abstract: The present invention relates to Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib, and/or AZD 2461, or a pharmaceutically acceptable salt thereof, for use in the treatment of impaired skin wound healing in a subject, an in vitro method for identifying a subject suffering from impaired skin wound healing to be responsive to the treatment with Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib and/or AZD 2461, and kits and kits-of-part related thereto.
    Type: Application
    Filed: April 24, 2018
    Publication date: March 12, 2020
    Applicant: AKRIBES BIOMEDICAL GMBH
    Inventors: BARBARA WOLFF-WINISKI, ANTON STÜTZ, PETRA DÖRFLER